Leoligin Systemic Delivery for Hypoxia-Induced Tissue Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological interventions for minimizing tissue damage due to oxygen deprivation, such as in myocardial infarction and stroke, are limited to secondary effects and require invasive procedures, failing to provide direct protection to undersupplied tissues, and non-invasive administration methods are inefficient for delivering sufficient drug amounts.
Innovation Solution
Systemic administration of leoligin or its derivatives, such as via inhalation or buccal/sublingual routes, to prevent and reduce tissue damage caused by hypoxia, using formulations like inhalers, nebulizers, or tablets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If direct injection of growth factors or leoligin derivatives into the tissue is used, then direct protective effect on undersupplied tissue is achieved, but invasive procedures are required and cannot be applied in the field
Solution Approach 1:
The patent uses blood as an intermediary carrier to transport the leoligin derivative from the injection site (peri-infarction zone) to the ischemic tissue. This allows the protective compound to reach the target tissue without requiring direct injection into the tissue itself, thereby maintaining therapeutic effectiveness while eliminating the need for invasive intratissular procedures.
Solution Approach 2:
The patent employs the body's own blood circulation system to deliver the therapeutic compound. By injecting the leoligin derivative into the peri-infarction zone and utilizing natural blood flow, the system harnesses the body's self-service mechanism (circulation) to achieve tissue protection without requiring external invasive intervention at the tissue level.
2Reliability
If immediate admission to emergency care facility with revascularization procedures is performed, then tissue damage is minimized, but valuable time is lost and invasive procedures are required
Solution Approach 1:
The patent applies preliminary action by administering the leoligin derivative to the peri-infarction zone before the actual tissue damage occurs or progresses. This preemptive treatment prevents further ischemic damage and facilitates collateral artery growth, reducing the need for immediate invasive revascularization procedures and minimizing time loss.
Solution Approach 2:
The patent converts the harmful effect of vascular occlusion and ischemia into a beneficial response by stimulating collateral artery growth. The leoligin derivative transforms the ischemic environment into a pro-angiogenic state, where the body's natural healing mechanisms are enhanced to restore blood supply, thereby reducing dependence on immediate invasive procedures.
3Ease of operation
If non-invasive administration methods (oral, inhalation) are used, then ease of operation is improved, but efficient delivery of sufficient drug amounts is not achieved
Solution Approach 1:
The patent utilizes the pneumatic and hydraulic properties of the respiratory system to deliver the leoligin derivative. By administering the compound via inhalation or nebulization, the drug is transported through the respiratory tract's fluid and gas dynamics directly to the bloodstream, achieving both non-invasive administration and efficient drug delivery through the body's natural pneumatic-hydraulic circulation.
Data Source
AI summary
The present invention provides for leoligin or a derivative thereof for use in the prevention and/or reduction of tissue damages, wherein leoligin or the derivative thereof is administered systemically to the subject in need thereof.